WallStreetZenWallStreetZen

NASDAQ: PROC
Procaps Group Sa Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

PROC past earnings growth

How has PROC's earnings growth performed historically?
Company
-13.33%
Industry
13.12%
Market
104.85%
PROC's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
PROC's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

PROC past revenue growth

How has PROC's revenue growth performed historically?
Company
-4.8%
Industry
10.04%
Market
17.15%
PROC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PROC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

PROC earnings and revenue history

Current Revenue
$414.1M
Current Earnings
$52.2M
Current Profit Margin
12.6%

PROC Return on Equity

Current Company
269.4%
Current Industry
10.7%
Current Market
-8.4%
PROC's Return on Equity (269.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when PROC announces earnings.

PROC Return on Assets

Current Company
11%
Current Industry
2.9%
PROC is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

PROC Return on Capital Employed

Current Company
19.66%
Current Industry
5.5%
PROC's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PROC vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
PROC$414.10M$75.58M$52.20M-61.31%-38.62%
ACB$199.23M-$66.17M-$106.90M+17.87%N/A
AQST$50.58M$1.18M-$7.87M-5.59%N/A
KMDA$142.52M$22.44M$8.28M+4.48%-20.93%
ESPR$116.33M-$150.11M-$209.25M-5.90%N/A
View Top Pharmaceutical Stocks

PROC earnings dates

Next earnings date
May 9, 2024

Procaps Group Sa Earnings & Revenue FAQ

What were PROC's earnings last quarter?

On Invalid Date, Procaps Group Sa (NASDAQ: PROC) reported Q3 2023 earnings per share (EPS) of $0.08, up 63.64% year over year. Total Procaps Group Sa earnings for the quarter were $8.19 million. In the same quarter last year, Procaps Group Sa's earnings per share (EPS) was $0.22.

If you're new to stock investing, here's how to buy Procaps Group Sa stock.

What was PROC's earnings growth in the past year?

As of Q2 2024, Procaps Group Sa's earnings has grown -13.33% year over year. This is 26.46 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 13.12%. Procaps Group Sa's earnings in the past year totalled $52.20 million.

What is PROC's earnings date?

Procaps Group Sa's earnings date is Invalid Date. Add PROC to your watchlist to be reminded of PROC's next earnings announcement.

What was PROC's revenue last quarter?

On Invalid Date, Procaps Group Sa (NASDAQ: PROC) reported Q3 2023 revenue of $118.41 million up 7.25% year over year. In the same quarter last year, Procaps Group Sa's revenue was $110.40 million.

What was PROC's revenue growth in the past year?

As of Q2 2024, Procaps Group Sa's revenue has grown -4.8% year over year. This is 14.84 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.04%. Procaps Group Sa's revenue in the past year totalled $414.10 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.